Contemporary RNA Therapeutics for Glioblastoma
Kaitlyn Melnick 1, Farhad Dastmalchi 2, Duane Mitchell 2, Maryam Rahman # 2, Elias J Sayour # 2Affiliations expand
- PMID: 34101090
- PMCID: PMC8186014
- DOI: 10.1007/s12017-021-08669-9
Free PMC article
Abstract
Glioblastoma (GBM) is the most common primary brain tumor in adults and is universally lethal with a median survival of less than two years with standard therapy. RNA-based immunotherapies have significant potential to establish a durable treatment response for malignant brain tumors including GBM. RNA offers clear advantages over antigen-focused approaches but cannot often be directly administered due to biological instability. This review will focus on utilization of RNA dendritic cell vaccines and RNA nanoparticle therapies in the treatment of GBM. RNA-pulsed dendritic cell vaccines have been shown to be safe in a small phase I clinical trial and RNA-loaded nanoparticle vaccines will soon be underway in GBM patients (NCT04573140).
Keywords: Dendritic cells; Glioblastoma; Immunotherapy; Nanoparticles; RNA; Vaccine.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
This manuscript discusses patented technologies by EJS and DAM that are under option to license by iOncologi, Inc., and patents by DAM that have been licensed to Immunomic Therapeutics, Inc., Annias Immunotherapeutics, Inc., and Celldex, Inc.
Figures
Similar articles
- A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.Rapp M, Grauer OM, Kamp M, Sevens N, Zotz N, Sabel M, Sorg RV.Trials. 2018 May 25;19(1):293. doi: 10.1186/s13063-018-2659-7.PMID: 29801515 Free PMC article.
- Emerging immunotherapies for glioblastoma.Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643.PMID: 27223671 Free PMC article. Review.
- Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.Jan CI, Tsai WC, Harn HJ, Shyu WC, Liu MC, Lu HM, Chiu SC, Cho DY.Front Immunol. 2018 May 29;9:727. doi: 10.3389/fimmu.2018.00727. eCollection 2018.PMID: 29910795 Free PMC article. Clinical Trial.
- A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials.Srivastava S, Jackson C, Kim T, Choi J, Lim M.Cancers (Basel). 2019 Apr 15;11(4):537. doi: 10.3390/cancers11040537.PMID: 30991681 Free PMC article. Review.
- Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.Hdeib A, Sloan AE.CNS Oncol. 2015;4(2):63-9. doi: 10.2217/cns.14.54.PMID: 25768330 Free PMC article. Review.
Cited by 1 article
- RNA-based therapeutics for neurological diseases.Anthony K.RNA Biol. 2022 Jan;19(1):176-190. doi: 10.1080/15476286.2021.2021650.PMID: 35067193 Free PMC article.
References
- Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New England Journal of Medicine. 2020;383(25):2427–2438. doi: 10.1056/NEJMoa2028436. – DOI – PMC – PubMed
Show all 20 references
Editor do blog: Julio Pereira – Neurocirugião – São Paulo CRM/SP 163.113 Site para Consulta: https://www.julio-pereira.com/ Consultório: (11)99503-8838 (WhatsApp) / (11)4200-2300 Atuando no Hospital Sírio-Libanês e na BP – A Beneficência Portuguesa de São Paulo.
CONFIRA NOSSOS SITES:
Cirurgia de Coluna
Tumor Cerebral
Aneurisma Cerebral
Radiocirurgia
Neuro Cancer
WeNeuro
